A stronger focus on oncology, and in particular well known targets such as the HER2 and HER3 proteins, marks a change in strategy for Hillstream BioPharma. 13 July 2023
The USA’s health technology assessor the Institute for Clinical and Economic Review (ICER) today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of two sickle cell disease gene therapies. 13 July 2023
Recursion, a tech-bio firm seeking to decode biology to industrialize drug discovery, has announced a $50 million investment by US tech firm NVIDIA (Nasdaq: NVDA), which was executed as a private investment in public equity (PIPE). 13 July 2023
French ophthalmology biotech company Nicox has provided details of a US market survey evaluating the commercial potential of its investigational drug NCX 470, a nitric oxide (NO)-donating bimatoprost aimed at treating angle ocular or ocular hypertension. 13 July 2023
As interest in advanced therapies continues to surge, a new ophthalmic specialist focused on cell-based medicines has been launched with $70 million in series A financing. 13 July 2023
ADC Therapeutics has announced a pause in patient enrollment in the Phase II LOTIS-9 trial of Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously-untreated diffuse large B-cell lymphoma. 12 July 2023
US gene therapy company Avrobio today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, joining a growing list of biotechs that have recently announced similar actions. 12 July 2023
The Swiss subsidiary of Sino-American biotech BeiGene and Swiss pharma giant Novartis on Tuesday entered into a mutual termination and release agreement to mutually terminate the option agreement, effective immediately. 12 July 2023
Boston, USA-based Crossbow Therapeutics, a biotech developing a new class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding round. 12 July 2023
Replicate Bioscience, a company pioneering self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease and other therapy areas, has appointed Rachael Lester as its chief business officer. 11 July 2023
Yesterday after market close, US genetic medicines company 4D Molecular Therapeutics announced a license agreement with Japanese drug major Astellas Pharma. 11 July 2023
Sino-American biotech BeiGene has entered an agreement with Duality Biologic (DualityBio) to acquire an exclusive option for a global clinical and commercial license to an investigational, pre-clinical antibody-drug conjugate (ADC) therapy for patients with select solid tumors. 11 July 2023
US pharma major Bristol Myers Squibb has exercised its option to enter into an exclusive global license agreement with German drug discovery company Evotec. 11 July 2023
China-based Brii Biosciences says that it has entered into license agreements with US firm VBI Vaccines, expanding the companies’ collaboration in the hepatitis B virus (HBV) field. 11 July 2023
Dublin, Ireland-headquartered protein specialist Prothena revealed that US pharma major Bristol Myers Squibb has exercised its option under the global neuroscience research and development collaboration to obtain the exclusive worldwide commercial rights for PRX005. 11 July 2023
Shares of French clinical-stage biotech Nanobiotix shot up more than 51% to 6.99 euros by early afternoon, having risen as high as 7.59 euros, on news of a lucrative licensing deal for its radioenhancer NBTXR3 with Janssen. 10 July 2023
US gene editing company Precision BioSciences and Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly, have amended and restated the development and license agreement that they signed in November 2020. 10 July 2023
Chinese biopharma firm Innovent Biologics and development partner IASO Biotherapies last week received approval from the China National Medical Product Administration (NMPA) for Fucaso (equecabtagene autoleucel) as a treatment for patients with relapsed or refractory multiple myeloma who have received ≥3 lines of prior therapies. 10 July 2023
The US Food and Drug Administration (FDA) has removed the partial clinical hold on the TakeAim Leukemia Phase I/II study of emavusertib for the treatment of hematologic malignancies, conducted by US biotech Curis. 7 July 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024